Exacis is developing potent, safe, and high-quality NK and T cell therapies to treat both solid tumors and hematologic malignancies. Our cells are produced based upon a Programmable Therapeutics Platform that consists of fully reprogrammed induced pluripotent stem cells (iPSCs) that are engineered with both stealthing and performance edits. The platform can be programmed by inserting either Chimeric Antigen Receptors (CAR) tar...
Exacis is developing potent, safe, and high-quality NK and T cell therapies to treat both solid tumors and hematologic malignancies. Our cells are produced based upon a Programmable Therapeutics Platform that consists of fully reprogrammed induced pluripotent stem cells (iPSCs) that are engineered with both stealthing and performance edits. The platform can be programmed by inserting either Chimeric Antigen Receptors (CAR) targeting desired antigens or by combining with monoclonal antibodies aimed at specific tumors.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.